ATE530066T1 - Verbindungen zur behandlung von stoffwechselstörungen - Google Patents
Verbindungen zur behandlung von stoffwechselstörungenInfo
- Publication number
- ATE530066T1 ATE530066T1 AT07757326T AT07757326T ATE530066T1 AT E530066 T1 ATE530066 T1 AT E530066T1 AT 07757326 T AT07757326 T AT 07757326T AT 07757326 T AT07757326 T AT 07757326T AT E530066 T1 ATE530066 T1 AT E530066T1
- Authority
- AT
- Austria
- Prior art keywords
- carbon atoms
- ring
- alkyl
- hydrogen
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- -1 perfluoromethoxy Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
- A01N31/08—Oxygen or sulfur directly attached to an aromatic ring system
- A01N31/14—Ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77767806P | 2006-02-28 | 2006-02-28 | |
| PCT/US2007/062574 WO2007101060A2 (en) | 2006-02-28 | 2007-02-22 | Compounds for the treatment of metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE530066T1 true ATE530066T1 (de) | 2011-11-15 |
Family
ID=38459732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07757326T ATE530066T1 (de) | 2006-02-28 | 2007-02-22 | Verbindungen zur behandlung von stoffwechselstörungen |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20100227901A1 (de) |
| EP (1) | EP1988772B1 (de) |
| JP (1) | JP2009528375A (de) |
| KR (1) | KR20080098615A (de) |
| CN (1) | CN101394738A (de) |
| AT (1) | ATE530066T1 (de) |
| AU (1) | AU2007220868B2 (de) |
| CA (1) | CA2642662A1 (de) |
| IL (1) | IL193321A0 (de) |
| MX (1) | MX2008011022A (de) |
| NZ (1) | NZ570100A (de) |
| WO (1) | WO2007101060A2 (de) |
| ZA (1) | ZA200806444B (de) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2314617B1 (de) | 2004-07-23 | 2015-06-24 | Acceleron Pharma Inc. | ActRII-Rezeptor-Polypeptide |
| US8173601B2 (en) | 2007-02-09 | 2012-05-08 | Acceleron Pharma, Inc. | Activin-ActRIIa antagonists and uses for treating multiple myeloma |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| KR101585623B1 (ko) | 2005-11-23 | 2016-01-19 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한이들의 용도 |
| NZ570334A (en) * | 2006-02-02 | 2011-07-29 | Wellstat Therapeutics Corp | Compounds for the treatment of metabolic disorders |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CN101835485B (zh) | 2007-02-01 | 2016-10-26 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂及在治疗或预防乳腺癌中的用途 |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JP2010539236A (ja) | 2007-09-18 | 2010-12-16 | アクセルロン ファーマ， インコーポレイテッド | アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用 |
| JP5496913B2 (ja) * | 2008-01-15 | 2014-05-21 | ウェルスタット セラピューティクス コーポレイション | 代謝異常の治療のための化合物 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| FI3750552T3 (fi) | 2008-08-14 | 2023-07-25 | Acceleron Pharma Inc | Gdf-loukkuja |
| MX2011013172A (es) | 2009-06-08 | 2012-04-02 | Acceleron Pharma Inc | Metodos para aumentar adipocitos termogenicos. |
| KR20210136174A (ko) | 2009-06-12 | 2021-11-16 | 악셀레론 파마 인코포레이티드 | 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질 |
| ES2869864T3 (es) * | 2009-11-03 | 2021-10-26 | Acceleron Pharma Inc | Procedimientos para el tratamiento de la enfermedad del hígado graso |
| EP3332796A1 (de) | 2009-11-17 | 2018-06-13 | Acceleron Pharma Inc. | Actriib-proteine und varianten davon sowie verwendungen davon zur utrophin-induktion für therapien gegen muskuläre dystrophie |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| KR20130132824A (ko) | 2010-11-08 | 2013-12-05 | 악셀레론 파마 인코포레이티드 | Actriia 결합제 및 이의 용도 |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8500260B2 (en) | 2011-04-27 | 2013-08-06 | Xerox Corporation | Ink compositions incorporating substituted oxazoline compounds or substituted oxazoline derivatives |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2567959B1 (de) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren |
| EP2760862B1 (de) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren |
| ES2884095T3 (es) | 2012-11-02 | 2021-12-10 | Celgene Corp | Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos |
| MX2016016531A (es) | 2014-06-13 | 2017-04-25 | Acceleron Pharma Inc | Metodos y composiciones para el tratamiento de las ulceras. |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| WO2016090077A1 (en) | 2014-12-03 | 2016-06-09 | Celgene Corporation | Activin-actrii antagonists and uses for treating anemia |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4824843A (en) * | 1987-06-25 | 1989-04-25 | Warner-Lambert Company | Substituted amide inhibitors of cholesterol absorption |
| JP3906935B2 (ja) * | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| ES2288957T3 (es) * | 2000-05-12 | 2008-02-01 | Ortho-Mcneil Pharmaceutical, Inc. | 4h-benzo(1.4)oxazin-3-ina biologicamente activas. |
| HU230352B1 (hu) * | 2001-06-12 | 2016-02-29 | Wellstat Therapeutics Corporation | Metabolikus rendellenességek kezelésére adható vegyületek és ezeket tartalmazó gyógyászati készítmények |
| JP2006507303A (ja) * | 2002-11-01 | 2006-03-02 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の処置のための化合物 |
| US7615575B2 (en) * | 2003-02-13 | 2009-11-10 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| ES2353601T3 (es) * | 2003-04-15 | 2011-03-03 | Wellstat Therapeutics Corporation | Compuestos para el tratamiento de trastornos metabólicos. |
| JP4697973B2 (ja) * | 2003-04-22 | 2011-06-08 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の処置のための化合物 |
| ATE526018T1 (de) * | 2003-04-30 | 2011-10-15 | Wellstat Therapeutics Corp | Verbindungen zur behandlung von stoffwechselstörungen |
| WO2005018628A1 (en) * | 2003-08-20 | 2005-03-03 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
-
2007
- 2007-02-22 EP EP07757326A patent/EP1988772B1/de not_active Not-in-force
- 2007-02-22 MX MX2008011022A patent/MX2008011022A/es active IP Right Grant
- 2007-02-22 CA CA002642662A patent/CA2642662A1/en not_active Abandoned
- 2007-02-22 WO PCT/US2007/062574 patent/WO2007101060A2/en not_active Ceased
- 2007-02-22 AT AT07757326T patent/ATE530066T1/de not_active IP Right Cessation
- 2007-02-22 AU AU2007220868A patent/AU2007220868B2/en not_active Ceased
- 2007-02-22 CN CNA2007800071537A patent/CN101394738A/zh active Pending
- 2007-02-22 JP JP2008557453A patent/JP2009528375A/ja active Pending
- 2007-02-22 KR KR1020087020406A patent/KR20080098615A/ko not_active Ceased
- 2007-02-22 US US12/279,808 patent/US20100227901A1/en not_active Abandoned
- 2007-02-22 NZ NZ570100A patent/NZ570100A/en not_active IP Right Cessation
-
2008
- 2008-07-24 ZA ZA200806444A patent/ZA200806444B/xx unknown
- 2008-08-07 IL IL193321A patent/IL193321A0/en unknown
-
2011
- 2011-08-25 US US13/217,977 patent/US20120071526A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007220868A1 (en) | 2007-09-07 |
| MX2008011022A (es) | 2008-09-10 |
| WO2007101060A2 (en) | 2007-09-07 |
| US20120071526A1 (en) | 2012-03-22 |
| EP1988772A2 (de) | 2008-11-12 |
| CN101394738A (zh) | 2009-03-25 |
| EP1988772B1 (de) | 2011-10-26 |
| KR20080098615A (ko) | 2008-11-11 |
| IL193321A0 (en) | 2009-08-03 |
| EP1988772A4 (de) | 2010-10-27 |
| NZ570100A (en) | 2011-01-28 |
| ZA200806444B (en) | 2009-05-27 |
| US20100227901A1 (en) | 2010-09-09 |
| CA2642662A1 (en) | 2007-09-07 |
| AU2007220868B2 (en) | 2011-06-09 |
| WO2007101060A3 (en) | 2007-12-13 |
| JP2009528375A (ja) | 2009-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE530066T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| WO2007087505A3 (en) | Compounds for the treatment of metabolic disorders | |
| WO2007095462A3 (en) | Compounds for the treatment of metabolic disorders | |
| CY1111310T1 (el) | Ενωσεις για την αγωγη μεταβολικων διαταραχων | |
| WO2007137008A3 (en) | Compounds for the treatment of metabolic disorders | |
| WO2004073611A3 (en) | Compounds for the treatment of metabolic disorders | |
| ATE526018T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| UA95613C2 (ru) | Соединения для лечения расстройсв метаболизма | |
| WO2004093806A3 (en) | Compounds for the treatment of metabolic disorders | |
| WO2007087506A3 (en) | Compounds for the treatment of metabolic disorders | |
| WO2007117791A3 (en) | Combination treatment of metabolic disorders | |
| WO2005105732A8 (en) | Substituted methyl aryl or heteroaryl amide compounds | |
| WO2008022267A3 (en) | Combination treatment for metabolic disorders | |
| TW200604175A (en) | Ortho substituted aryl or heteroaryl amide compounds | |
| NO20003399D0 (no) | <Alfa>-amionoamidderivater som er nyttige som smertestillende midler | |
| UA88772C2 (ru) | Соединения для лечения расстройств метаболизма | |
| WO2007087504A3 (en) | Compounds for the treatment of metabolic disorders | |
| EP1868595A4 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| WO2007092729A3 (en) | Compounds for the treatment of metabolic disorders | |
| HK1126089A (zh) | 代謝紊亂的組合治療 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |